Endpoints News 24. Nov. 2025 J&J’s tau-targeting antibody fails Phase 2 Alzheimer's study #fails Phase #Alzheimer study
BioPharma Dive 24. Nov. 2025 Bayer’s experimental blood-thinner notches trial win in stroke prevention #Asundexian Phase #prevention Asundexian
BioWorld 24. Nov. 2025 Bayer’s asundexian hits phase III stroke goal in win for FXIa drugs #phase III #drugs Detailed
BioWorld 24. Nov. 2025 Novo’s semaglutide fails in phase III Alzheimer’s trials #phase III #III Alzheimer
BioWorld 24. Nov. 2025 Novo’s semaglutide fails in phase III Alzheimer’s trials #III Alzheimer #phase III
Endpoints News 21. Nov. 2025 Contineum's J&J-partnered drug fails Phase 2 multiple sclerosis trial #Thursday afternoon #fails Phase
Roche Media 18. Nov. 2025 Roche reports positive Phase III data of giredestrant for breast cancer - Clinical Trials Arena #Phase III #Clinical Trials
Roche Media 11. Nov. 2025 Roche sizes up first BTK inhibitor approval on Phase III MS victory - Clinical Trials Arena #Phase III #Clinical Trials
Roche Media 10. Nov. 2025 Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed - Fierce Biotech #BTK inhibitor #Fierce Biotech
Roche Media 3. Nov. 2025 Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint - Clinical Trials Arena #Phase III #III trial